You are here

Press releases


Barcelona, July 26, 2022. -Investment in health startups in the BioRegion of Catalonia set a new record in the first half of the year: €296 million, more than all funding secured in 2021 (€238 million). This period (January to July) was the best ever, fueled once again by venture capital, which totaled €258 million, or 87% of the capital raised, followed by the stock market, public grants and crowdequity.



Barcelona, 18 May 2022.- Catalonia is participating in over 1,200 clinical trials currently underway to test new therapies and drugs in patients. This puts the BioRegion 6th in Europe in number of trial participations and 8th in the world.

Catalonia is only surpassed in number of participations in active studies by large countries like the United States (9,532), Canada (1,905), France (1,896), United Kingdom (1,633), Spain (1,595), Germany (1,583) and Italy (1,460). The data also shows that Catalan centers take part in 75% of all active trials run in Spain,...


Tuesday, 10 May 2022, Madrid and Barcelona. - The Spanish Bioindustry Association (AseBio) announced this Tuesday that BIOSPAIN, one of the biggest international biotechnology events in southern Europe, will take place from 26 to 28 September 2023 in Barcelona, in collaboration with Biocat, the Government of Catalonia and the Barcelona City Council.  

For Biocat CEO Robert Fabregat, Barcelona being chosen to host BIOSPAIN “confirms the Catalan capital’s strategic position as one of the main cities on the map for life sciences and...


Barcelona, January 26, 2022. Investment in health startups in the BioRegion continues to grow and again surpassed the €200 million mark for the second year in a row, despite the COVID-19 pandemic. In total, companies raised €238 million, the most to date. Venture capital funding was the main driver of this growth, with more than €187 million, or 79% of all capital, three times as much as in 2019.

83% of the venture capital raised was in operations with international investors. In fact, more than 90% of operations worth over €10 million are...

  • Five spin-offs and six start-ups comprise the first generation of companies accelerated at the BCN Health Booster, an initiative promoted by the University of Barcelona Science Park and the Barcelona City Council, with support from Barcelona Activa and collaboration from Biocat.
  • The eleven companies selected from a total of nineteen applications are: Aptadel Therapeutics, Artificial Nature, Bioliquid Innovative Genetics, DeepUll, GAT Biosciences, GAT Therapeutics, MiMARK, Nuage Therapeutics, Ona Therapeutics, Oncoheroes Biosciences and...
  • The climate crisis, overpopulation and a hyperconnected, globalized world make us the animal species most susceptible to pandemics like the current one.
  • To prevent future threats and be better prepared for dealing with them, we have to adopt a ‘one health’ approach: considering human health as it relates to animal and environmental health.
  • On November 16 and 17, the ”la Caixa” Foundation and Biocat are hosting the international conference “Pandemics: Overcoming Covid-19 and preparing for the future”. This virtual event will bring together...